Back to Search Start Over

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective

Authors :
T, Koessler
M, Alsina
D, Arnold
I, Ben-Aharon
M, Collienne
M P, Lutz
C, Neuzillet
R, Obermannova
M, Peeters
F, Sclafani
E, Smyth
J W, Valle
A D, Wagner
L, Wyrwicz
E, Fontana
M, Moehler
Institut Català de la Salut
[Koessler T] Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. [Alsina M] Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arnold D] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. [Ben-Aharon I] Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel. [Collienne M] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. European Organisation for Research and Treatment of Cancer, Brussels, Belgium. [Lutz MP] Caritasklinikum, Saarbrucken, Germany
Vall d'Hebron Barcelona Hospital Campus
Source :
ESMO Open, Scientia
Publication Year :
2022
Publisher :
Elsevier BV, 2022.

Abstract

Neuroendocrine tumours; Pancreatic cancer; Stomach cancer Tumores neuroendocrinos; Cáncer de páncreas; Cáncer de estómago Tumors neuroendocrins; Càncer de pàncrees; Càncer d'estómac There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future. This work was supported by a donation from the Swiss Cancer Research Foundation from Switzerland. MC was supported by a grant by EORTC Cancer Research Fund (ECRF) and the Gastrointestinal Tract Cancer Group.

Subjects

Subjects :
Cancer Research
Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Immunoteràpia
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Medical Oncology
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
Estómac - Càncer - Tractament
Oncology
Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms [DISEASES]
neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales [ENFERMEDADES]
Humans
Immunotherapy
Human medicine
Gastrointestinal Neoplasms
Aparell digestiu - Càncer - Tractament

Details

ISSN :
20597029
Volume :
7
Database :
OpenAIRE
Journal :
ESMO Open
Accession number :
edsair.doi.dedup.....309f94a6d5ee2f8ecf9e38960af9993c
Full Text :
https://doi.org/10.1016/j.esmoop.2022.100392
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details